Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) EBITDA (2019 - 2025)

Benitec Biopharma has reported EBITDA over the past 7 years, most recently at -$12.0 million for Q4 2025.

  • Quarterly results put EBITDA at -$12.0 million for Q4 2025, down 69.74% from a year ago — trailing twelve months through Dec 2025 was -$44.3 million (down 109.46% YoY), and the annual figure for FY2025 was -$37.9 million, down 73.58%.
  • EBITDA reached -$12.0 million in Q4 2025 per BNTC's latest filing, down from -$8.9 million in the prior quarter.
  • Across five years, EBITDA topped out at -$3.5 million in Q1 2022 and bottomed at -$14.5 million in Q1 2025.
  • Median EBITDA over the past 5 years was -$4.8 million (2021), compared with a mean of -$6.2 million.
  • The largest annual shift saw EBITDA grew 12.6% in 2024 before it plummeted 249.09% in 2025.
  • Over 5 years, EBITDA stood at -$4.9 million in 2021, then dropped by 14.21% to -$5.6 million in 2022, then dropped by 25.11% to -$7.0 million in 2023, then decreased by 1.18% to -$7.1 million in 2024, then crashed by 69.74% to -$12.0 million in 2025.
  • Business Quant data shows EBITDA for BNTC at -$12.0 million in Q4 2025, -$8.9 million in Q3 2025, and -$8.9 million in Q2 2025.